Evidence map›Paper›PMID 40128782›Full record

ArticleJournal of nanobiotechnology2025

Reduction of colitis in mice by chemically programmed supramolecular nanoassemblies of vitamin-lipid conjugates.

Shiyun Xian, Fanchao Meng, Xiaona Chen, Liqing Zhu, Hangxiang Wang

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shiyun Xian *Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong Province, 250118, P. R. China.
Fanchao Meng *Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong Province, 250118, P. R. China.
Xiaona ChenDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, P. R. China.
Liqing ZhuDepartment of Clinical Laboratory, Peking University Cancer Hospital and Institute, Beijing, P. R. China. wzzhuliqing@126.com.
Hangxiang WangJinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong Province, 250118, P. R. China. wanghx@zju.edu.cn.

Funding

Beijing Natural Science foundation 7252006National Natural Science Foundation of China 82273490Natural Science Foundation of Shandong Province ZR2023ZD59Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2023-PT320-02"Pioneer" and "Leading Goose" R&D Program of Zhejiang Province 2025C01217Research Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2022010B
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a relapsing disorder characterized by uncontrolled chronic inflammation of the gastrointestinal tract, posing a significant therapeutic challenge owing to the limited efficacy and undesirable side effects of current therapeutic options. A key pathological hallmark of IBD is the excessive production of reactive oxygen species (ROS). Hence, therapeutic strategies aimed at reducing ROS levels are promising for relieving these inflammatory conditions. Vitamin C-a natural nutrient for the human body-is well known for its potent antioxidant effects. However, the clinical development of vitamin C as a therapeutic drug has been hindered by its poor stability, rapid metabolism, and inadequate tissue accumulation. Herein, we report that the bioavailability of vitamin C can be enhanced by chemically reprogramming it with a small panel of long-chain fatty acids that aid in the aqueous self-assembly of the resulting drug conjugates to create self-deliverable nanoassemblies, enhancing their inflammation disease-oriented delivery and cellular uptake. In mice with dextran sulfate sodium-induced colitis, the optimal vitamin C-lipid nanoassemblies preferentially accumulated in inflamed colonic tissues following systemic administration and substantially ameliorated disease severity. We extended this strategy to incorporate the clinically approved glucocorticoid budesonide into the vitamin C nanosystem, facilitating a synergistic combination. In the chronic colitis model, the combination treatment reduced inflammation without compromising global immunity. Mechanistically, the treatment modulated the intestinal inflammatory microenvironment and altered the immune cell landscape, partly through regulation of the gut microbiome. Given its anticipated negligible side effects, this novel nanoassembly platform leveraging small-molecule lipidation may become a promising therapeutic for treating various inflammatory diseases.

Indexed as

Ascorbic AcidColitisLipidsNanoparticlesAnimalsAnti-Inflammatory AgentsBudesonideDextran SulfateDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLReactive Oxygen SpeciesAnti-Inflammatory AgentsAscorbic AcidBudesonideDextran SulfateLipidsReactive Oxygen SpeciesBudesonideInflammatory bowel diseaseLipid conjugateSelf-assemblyVitamin C

Identifiers

PMID40128782
PMCPMC11934663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.